Mostrar el registro sencillo del ítem
dc.contributor.author
Keaveny, Tony M.
dc.contributor.author
Crittenden, Daria B.
dc.contributor.author
Bolognese, Michael A.
dc.contributor.author
Genant, Harry K.
dc.contributor.author
Engelke, Klaus
dc.contributor.author
Oliveri, María Beatriz
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Brown, Jacques P.
dc.contributor.author
Langdahl, Bente L.
dc.contributor.author
Yan, Chris
dc.contributor.author
Grauer, Andreas
dc.contributor.author
Libanati, Cesar
dc.date.available
2018-08-23T21:07:35Z
dc.date.issued
2017-09
dc.identifier.citation
Keaveny, Tony M.; Crittenden, Daria B.; Bolognese, Michael A.; Genant, Harry K.; Engelke, Klaus; et al.; Greater Gains in Spine and Hip Strength for Romosozumab Compared With Teriparatide in Postmenopausal Women With Low Bone Mass; American Society for Bone and Mineral Research; Journal of Bone and Mineral Research; 32; 9; 9-2017; 1956-1962
dc.identifier.issn
0884-0431
dc.identifier.uri
http://hdl.handle.net/11336/56921
dc.description.abstract
Romosozumab is a monoclonal antibody that inhibits sclerostin and has been shown to reduce the risk of fractures within 12 months. In a phase II, randomized, placebo-controlled clinical trial of treatment-naïve postmenopausal women with low bone mass, romosozumab increased bone mineral density (BMD) at the hip and spine by the dual effect of increasing bone formation and decreasing bone resorption. In a substudy of that trial, which included placebo and teriparatide arms, here we investigated whether those observed increases in BMD also resulted in improvements in estimated strength, as assessed by finite element analysis. Participants received blinded romosozumab s.c. (210 mg monthly) or placebo, or open-label teriparatide (20 μg daily) for 12 months. CT scans, obtained at the lumbar spine (n = 82) and proximal femur (n = 46) at baseline and month 12, were analyzed with finite element software (VirtuOst, O.N. Diagnostics) to estimate strength for a simulated compression overload for the spine (L1 vertebral body) and a sideways fall for the proximal femur, all blinded to treatment assignment. We found that, at month 12, vertebral strength increased more for romosozumab compared with both teriparatide (27.3% versus 18.5%; p = 0.005) and placebo (27.3% versus –3.9%; p < 0.0001); changes in femoral strength for romosozumab showed similar but smaller changes, increasing more with romosozumab versus teriparatide (3.6% versus –0.7%; p = 0.027), and trending higher versus placebo (3.6% versus −0.1%; p = 0.059). Compartmental analysis revealed that the bone-strengthening effects for romosozumab were associated with positive contributions from both the cortical and trabecular bone compartments at both the lumbar spine and hip. Taken together, these findings suggest that romosozumab may offer patients with osteoporosis a new bone-forming therapeutic option that increases both vertebral and femoral strength within 12 months.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
American Society for Bone and Mineral Research
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by/2.5/ar/
dc.subject
Anabolics
dc.subject
Osteoporosis
dc.subject
Romosozumab
dc.subject
Teriparatide
dc.subject.classification
Salud Ocupacional
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
Ciencias de la Salud
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.title
Greater Gains in Spine and Hip Strength for Romosozumab Compared With Teriparatide in Postmenopausal Women With Low Bone Mass
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2018-06-05T20:14:06Z
dc.journal.volume
32
dc.journal.number
9
dc.journal.pagination
1956-1962
dc.journal.pais
Estados Unidos
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.description.fil
Fil: Keaveny, Tony M.. University of California at Berkeley; Estados Unidos
dc.description.fil
Fil: Crittenden, Daria B.. Amgen Inc.; Estados Unidos
dc.description.fil
Fil: Bolognese, Michael A.. Bethesda Health Research Center; Estados Unidos
dc.description.fil
Fil: Genant, Harry K.. Synarc; Estados Unidos. University of California; Estados Unidos
dc.description.fil
Fil: Engelke, Klaus. Universitat Erlangen-Nuremberg; Alemania. Institute of Medical Physics Erlangen Germany; Alemania
dc.description.fil
Fil: Oliveri, María Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Inmunología, Genética y Metabolismo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Inmunología, Genética y Metabolismo; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina
dc.description.fil
Fil: Brown, Jacques P.. Laval University; Canadá
dc.description.fil
Fil: Langdahl, Bente L.. University Aarhus; Dinamarca
dc.description.fil
Fil: Yan, Chris. Amgen Ltd.; Reino Unido
dc.description.fil
Fil: Grauer, Andreas. Amgen Inc.; Estados Unidos
dc.description.fil
Fil: Libanati, Cesar. Union Chimique Belge; Bélgica
dc.journal.title
Journal of Bone and Mineral Research
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1002/jbmr.3176
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/abs/10.1002/jbmr.3176
Archivos asociados